Key result
PRXL2B knockdown plus oncolytic adenovirus H101 suppresses hepatocellular carcinoma growth via the PI3K/AKT/PD-L1 axis.
Why the study?
Oncolytic adenovirus H101 has shown antitumor activity in hepatocellular carcinoma, but the molecular determinants of treatment response remain unclear.
Does PRXL2B knockdown enhance the antitumor effect of oncolytic adenovirus H101 in hepatocellular carcinoma models?
Does PRXL2B knockdown enhance the antitumor effect of oncolytic adenovirus H101 in hepatocellular carcinoma models?
PRXL2B knockdown enhances the therapeutic efficacy of oncolytic adenovirus H101 in hepatocellular carcinoma by modulating the PI3K/AKT/PD-L1 axis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PRXL2B as H101 response determinant in HCC models; leaves open clinical validation and therapeutic translation.
Oncolytic adenovirus H101 has shown antitumor activity in hepatocellular carcinoma (HCC), but the molecular determinants of treatment response remain unclear. In this study, a Hepa1-6 subcutaneous tumor model was established in C57BL/6 mice and treated with intratumoral H101, followed by integrated transcriptomic and proteomic analyses to identify candidate genes associated with H101 response. PRXL2B was selected for further investigation using public multi-omics datasets, tissue microarray-based immunohistochemistry, in vitro functional assays, mechanistic analyses, and in vivo validation experiments. Integrated multi-omics analyses identified PRXL2B as a candidate gene downregulated after H101 treatment. Public datasets and tissue-based validation further showed that PRXL2B was upregulated in HCC tissues. In MHCC97H and HCCLM3 cells, PRXL2B knockdown inhibited proliferation, migration, and invasion, promoted apoptosis and cell-cycle arrest, and enhanced the antitumor effect of H101. Mechanistically, PRXL2B silencing reduced AKT phosphorylation and PD-L1 expression. In vivo , PRXL2B knockdown suppressed tumor growth, and the combination of PRXL2B knockdown and H101 produced the strongest antitumor effect. These findings indicate that PRXL2B promotes malignant phenotypes in HCC and may modulate H101 efficacy through the PI3K/AKT/PD-L1 axis. Targeting PRXL2B may therefore represent a potential strategy to enhance the therapeutic efficacy of oncolytic virus therapy in HCC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Hepatocellular carcinoma (HCC) (n=84). PRXL2B knockdown and oncolytic adenovirus H101 vs. Negative control (NC) / PBS was evaluated on Tumor weight at day 14 (in vivo model) (p=0.027). PRXL2B knockdown combined with oncolytic adenovirus H101 significantly suppressed hepatocellular carcinoma tumor growth and inhibited malignant phenotypes via the PI3K/AKT/PD-L1 axis.
Synapse has enriched 10 related papers. Consider them for comparative context: